Table 4.

Comparison of CR, PR, and NRa

NRPRCRPPost Hoc
N10911755
At onset
    gender (% female)293245NS
    ethnicity (% white/black/Asian/other)75/8/8/966/11/9/1367/8/17/8NS
    age45 ± 1742 ± 1640 ± 16NS
    BMI27 (15–47)27 (17–49)26 (18–45)NS
    MAP (mmHg)108 ± 15107 ± 15104 ± 16NS
    CrCl (ml/min per 1.73 m2)67 ± 3076 ± 3277 ± 30NS
    proteinuria (g/d)4.0 (0.4–19.6)4.7 (0.2–98.3)6.6 (0.2–41.0)<0.001NR,PR<CR
Follow-up
    duration of follow-up (mo)50 (12–273)64 (12–346)93 (14–315)<0.001NR<PR<CR
    time to remissionb (mo)12 (1–153)14 (2–197)NS
    peak proteinuriac7.5 (3.5–43.5)6.9 (3.5–98.3)7.2 (3.8–41.0)NS
    MAPc (mmHg)104 ± 11101 ± 896 ± 8<0.001NR>PR>CR
    antihypertensive medicationsc (n)1.1 (0–4.2)1.3 (0–3.8)0.8 (0–2.9)<0.001NR,PR>CR
    immunosuppressionc (%)
        high-dose corticosteroidsc334975<0.001NR<PR<CR
        cytotoxicc151117NS
        cyclosporin9118NS
        any form516689<0.001NR<PR<CR
    ACEi or ARB therapyc (%)435031NS
Outcome
    slope (ml/min per 1.73 m2/mo)−0.88 ± 1.00−0.47 ± 0.65−0.02 ± 0.36<0.001NR>PR>CR
    relapsed (%)5641NS
    renal failure (%)45186<0.001eNR>PR>CR
  • a Normally distributed variables (expressed as mean ± SD) are compared using one-way ANOVA with post hoc analysis using the least significant difference method for significant results. Nonparametric variables (expressed as median and range) are compared using Kruskal-Wallis with post hoc analysis using the Mann-Whitney test for significant results. Categorical variables were expressed in percentage and compared using χ2 test.

  • b Measured from first nephrotic measurement.

  • c Information from first clinical assessment up until remission for PR and CR groups.

  • d Patients with no proteinuria measurements after remission were excluded from the denominator.

  • e Log-rank test.